Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More
Executive Summary
Sponsors and payers question guidances' scope and potential audiences, and wonder if the agency couldn't just perform some retrospective audits of off-label communication to speed things up.
You may also be interested in...
Off-Label Discussion, But No Additions, For House User Fee Bill
Several Republicans remain interested in expanding off-label communications, suggesting the issue could come up outside the user fee context, potentially as part of future drug pricing discussions.
Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?
Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.
Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?
Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.